A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(15 sites)

United States

Study Site 016, Little Rock, Arkansas

Study Site 013, Orange, California

Study Site 020, San Diego, California

Study Site 019, San Diego, California

Study Site 001, Gainesville, Florida

Study Site 018, Miami, Florida

Study Site 010, Orlando, Florida

Study Site 014, Indianapolis, Indiana

Study Site 012, Lexington, Kentucky

Study Site 002, Boston, Massachusetts

Study Site 006, St Louis, Missouri

Study Site 003, Durham, North Carolina

Study Site 021, Cleveland, Ohio

Study Site 022, Fort Worth, Texas